Navigation Links
Cincinnati Children's earns $12 million NIH grant to test migraine prevention medicines
Date:9/28/2011

Cincinnati Children's Hospital Medical Center has received a $12 million grant from the National Institutes of Health to conduct the first clinical trial to determine the medication of choice for preventing migraines in children and teens.

Migraines affect more than six million children and adolescents in the United States, with an annual economic impact of $36 billion. There is no FDA-approved medication to prevent childhood migraines and there are no evidence-based studies.

The five-year study, to be conducted at up to 40 sites throughout the United States, will be led by Andrew Hershey, MD, PhD, and Scott Powers, PhD, who co-direct the Headache Center at Cincinnati Children's, which will serve as the clinical coordinating center. The University of Iowa has received a $5.8 million grant to serve as the data coordinating center for the study. Christopher Coffey, PhD, at the University of Iowa, will be principal investigator for the data coordinating center.

"Children and teens miss more than 130,000 school days every two weeks due to migraines," says Dr. Hershey. "The negative impact of having migraines on overall quality of life is similar to childhood cancer, heart disease and rheumatic disease," adds Dr. Powers.

The study will compare amitriptyline and topiramate the two medications headache specialists often prescribe to prevent childhood migraines. The study will involve 675 children and adolescents between the ages of 8 and 17.

Amitriptyline, first developed in 1961, is a drug originally used to treat depression but has long been used to prevent headaches. Topiramate is a newer medication used to treat epilepsy and approved to treat migraines in adults. Both drugs have been studied in adults but have been subjected to limited evidence-based research in children to determine their relative benefit in preventing migraines. Because of the side effects of each medication, it is essential that they be compared to placebo, says Dr. Hershey.

"The central problem for advancing care in pediatric headache medicine is the lack of placebo-controlled clinical trials and comparative effectiveness studies of preventive medication therapy," says Dr. Powers.

The study is intended to:

  • determine which drug is superior for reducing migraine frequency and disability
  • estimate how well each drug is tolerated
  • determine the "safety profiles" of each therapy

"Pediatric migraine is one of the five most prevalent childhood disorders in the United States," says Dr. Hershey, who also serves as interim director of the division of Neurology at Cincinnati Children's.

"Determining the optimal first-line prevention medication therapy will have a transformational impact on the field," adds Dr. Powers, who also directs the Office for Clinical and Translational Research at Cincinnati Children's, a group that will provide critical support to this effort. "The results of this trial will change current clinical practice by ensuring that decisions on early, effective treatment for millions of children and adolescents with migraine can now be based upon sound evidence."


'/>"/>

Contact: Jim Feuer
jim.feuer@cchmc.org
513-636-4656
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Related medicine news :

1. University of Cincinnati team to track tumor DNA through bloodstream
2. University of Cincinnati neurotrauma team awarded $2.1M to test lab on a tube
3. Doctor at Cincinnati Childrens receives prestigious NIH MERIT Award
4. HOCHMAN & PLUNKETT Opens Office in Cincinnati
5. ISSA Applauds Cincinnati Trainer Anthony Reed for Dedication to Health Awareness
6. UniqueU Medical Weight Loss Program Opens Cincinnati Location
7. Researcher at Childrens Hospital LA discovers way to overcome radiation resistance in leukemia
8. Parents Want Electronic Access to Their Childrens Docs: Survey
9. Fellow earns award for breast cancer research
10. Peppermint earns respect in mainstream medicine
11. Northwestern Medicine multiple sclerosis program earns national designation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... enough sleep affects much more than energy – it also has mental and physical benefits. ... motor reaction time, which can increase the risk of having a car accident. , ... the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to stay,” said ... Global Climate Change and Your Health on Voice America sponsored by Nature’s Tears® ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology: